Orthocell Ltd · ASX:OCC
Orthocell — Investor Presentation (May 2019)
18 slides from Orthocell's investor presentation, May 2019
Slide 1: Investor presentation
Investor presentation Finance News Network May 2019
Slide 2: Regenerative medicine
Regenerative medicine What is regenerative Why is regenerative What is Orthocell‘s position medicine? medicine a promising field? in this space? A new field of medicine seeking Ageing population and rising Orthocell is a world leading to repair injured or diseased musculoskeletal disorders regenerat
Slide 3: Board of directors
Board of directors Experienced Board with prior success commercialising regenerative medicine Dr Stewart James Washer Paul Anderson Matthew Callahan Professor Lars Lidgren Mr Qi Xiao Zhou Chairman Managing Director Board Member Board Member Board Member • 20+ years’ CEO and • 20+ years’ • Developed
Slide 4: Innovative products
Innovative products Orthocell is a regenerative medicine company delivering breakthrough products that restore mobility and function • Approved for sale in Europe (CE Mark)1 • 26% superior clinical performance1 CelGro® • Platform technology – multiple indications • Optimised manufacturing capabiliti
Slide 5: CelGro®
CelGro® A unique collagen medical device that augments tissue repair and regeneration
Slide 6: CelGro®: initial focus in bone regeneration
CelGro®: initial focus in bone regeneration Orthocell’s initial focus is on driving sales of CelGro® in the lucrative EU market CelGro®: a true regenerative medicine scaffold Illustrative example ü Superior tissue repair unique regenerative Defect Site - insufficient bone medicine qualities volume a
Slide 7: CelGro®: bone regeneration market opportunity
CelGro®: bone regeneration market opportunity Very favourable market dynamics Superior clinical performance (QT Score1) No product innovation to the dental Up to 26% better market globally quality newly 4.56 formed bone Existing products have inferior 3.46 functionality and handling 3.00 characteris
Slide 8: CelGro®: accelerating sales in dental bone
CelGro®: accelerating sales in dental bone With optimised and scalable manufacturing in place, regulatory approval achieved and KOL’s appointed, Orthocell is well placed to execute on its marketing and sales strategy Educating clinicians Marketing data Roll out KOL-lead clinician Generate supplement
Slide 9: CelGro® strategic focus
CelGro® strategic focus Orthocell is driving market entry for bone repair, leveraging EU approval to accelerate introduction of the tendon and soft tissue indications Near to medium term Medium term Medium to long term US$0.6bn US$0.9bn US$1.1bn Addressable Addressable Addressable market1 market1 ma
Slide 10: CelGro® nerve repair market opportunity
CelGro®- nerve repair market opportunity CelGro® is designed for suture-less reconnection of severed or damaged nerves, guiding nerve Very favourable market dynamics: regeneration and accelerating the healing process • Millions of people suffer from peripheral nerve injury as a result of motor-vehic
Slide 11: CelGro® revolutionising nerve repair
CelGro®- revolutionising nerve repair Patients regain increased sensation and muscle function in affected limbs following CelGro® nerve regeneration treatment Trial participant nerve injuries: First patients complete nerve regeneration trial: • Result in complete paralysis or impaired ü Regain sensa
Slide 12: Next steps
Next steps ontho-Cell
Slide 13: Regenerative medicine case study: PolyNovo
Regenerative medicine case study: PolyNovo Orthocell is well positioned to deliver significant shareholder upside in the near term Price (A$) Rerating based on: 0.7 • CelGro® gaining traction in key markets Revenue traction TGA approval 0.6 • Achieving US approval for CelGro® • Potential to address
Slide 14: Corporate overview
Corporate overview Orthocell is a regenerative medicine company delivering breakthrough products that restore mobility and function Share price performance Trading information 0.40 2,000 Share price (06-May-19) A$0.1150 Shares on issue1 120.7m 1,600 0.30 Market capitalisation ~A$14m Cash (as at 31-M
Slide 15: Upcoming catalysts
Upcoming catalysts CelGro® - Dental Roll out European education program Ongoing Commence European advertising campaign 2Q CY2019 Italy and UK sales growth 3Q CY2019 Spain and Germany market entry 3Q CY2019 Australian market authorisation 4Q CY2019 US market authorisation 1Q CY2020 CelGro® - Orthopae
Slide 16: Key investment highlights
Key investment highlights Significant upside Significant market interest Addressable markets worth >US$10bn p.a. De-risked product portfolio Substantial clinical data CE Mark (EU) achieved for CelGro1 Validated manufacturing process GMP-certified and TGA-licensed manufacturing capabilities Credentia
Slide 17: Disclaimer
Disclaimer This presentation prepared by Orthocell Ltd ("Company") does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or tr
Slide 18: Contact us
Contact us Paul Anderson Visit us Orthocell Limited www. orthocell.com.au Follow us on social media Founder and Managing Director P: +61 8 9360 2888 E: paulanderson@orthocell.com.au 18 Orthocell investor update